245 related articles for article (PubMed ID: 21052661)
1. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Claringbold PG; Brayshaw PA; Price RA; Turner JH
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):302-11. PubMed ID: 21052661
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
3. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
4. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
van Essen M; Krenning EP; Kam BL; de Herder WW; van Aken MO; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):743-8. PubMed ID: 18188559
[TBL] [Abstract][Full Text] [Related]
5. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
Hubble D; Kong G; Michael M; Johnson V; Ramdave S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1869-75. PubMed ID: 20445977
[TBL] [Abstract][Full Text] [Related]
6. Prospective observational study of
Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803
[TBL] [Abstract][Full Text] [Related]
7. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Claringbold PG; Turner JH
Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
[TBL] [Abstract][Full Text] [Related]
9. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
10.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
12. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.
Sabet A; Haslerud T; Pape UF; Sabet A; Ahmadzadehfar H; Grünwald F; Guhlke S; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):205-10. PubMed ID: 24030668
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.
van Essen M; Krenning EP; Kam BL; de Herder WW; Feelders RA; Kwekkeboom DJ
J Nucl Med; 2010 Mar; 51(3):383-90. PubMed ID: 20150247
[TBL] [Abstract][Full Text] [Related]
14. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
[TBL] [Abstract][Full Text] [Related]
15. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
16. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
17. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
19. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.
Ezziddin S; Khalaf F; Vanezi M; Haslerud T; Mayer K; Al Zreiqat A; Willinek W; Biersack HJ; Sabet A
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):925-33. PubMed ID: 24504504
[TBL] [Abstract][Full Text] [Related]
20. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.
Swärd C; Bernhardt P; Ahlman H; Wängberg B; Forssell-Aronsson E; Larsson M; Svensson J; Rossi-Norrlund R; Kölby L
World J Surg; 2010 Jun; 34(6):1368-72. PubMed ID: 20066413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
